Weekly eloralintide for people with obesity or overweight but no diabetes
Tests weekly eloralintide in people with obesity or overweight, without diabetes.
Plain-language title generated from the registry record
Registry title: A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
Key facts
- Where
- Brasília, Campinas, Fortaleza, Marília, Porto Alegre, Rio de Janeiro, and São Paulo, BrazilSee the 8 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with obesity, or with overweight plus a weight-related health condition, who do not have diabetes.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- BMI of 30 kg/m2 or more, or BMI of 27 kg/m2 or more with high blood pressure, dyslipidemia, obstructive sleep apnea or heart disease. No type 1 or type 2 diabetes.
- Earlier treatment
- At least one self-reported unsuccessful diet effort to lose weight. No weight-loss medicines or remedies in the last 90 days. No past or planned weight-loss surgery, endoscopic procedure or device therapy, with some exceptions.
Main reasons for not taking part
- Type 1 or type 2 diabetes
- Weight change of 5% or more in the 90 days before screening
- Heart attack, stroke, coronary artery revascularization, unstable angina or hospital stay for heart failure in the last 90 days
- Class IV congestive heart failure
- Prior or planned surgery, endoscopic procedure or device therapy for obesity, with some exceptions
Read by machine on 9 November 2026.
Where in Brazil
- Chronos Pesquisa ClínicaBrasília, BrazilNot yet recruiting
- Instituto de Pesquisa Clínica de CampinasCampinas, BrazilNot yet recruiting
- Private Practice - Dr.Miguel N. HissaFortaleza, BrazilNo longer taking part
- Centro de Pesquisa Clínica de Marília - CPCLIMMarília, BrazilNot yet recruiting
- Nucleo de Pesquisa Clínica do Rio Grande do SulPorto Alegre, BrazilNot yet recruiting
- IBPClin - Instituto Brasil de Pesquisa ClínicaRio de Janeiro, BrazilNot yet recruiting
- Ruschel Medicina e Pesquisa ClínicaRio de Janeiro, BrazilNot yet recruiting
- CEPIC - Centro Paulista de Investigação ClínicaSão Paulo, BrazilNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07321886EU 2025-523657-34-00
- Record updated
- 22 September 2026
- Original description
The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase.Read full original descriptionShow less
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Obesity or Overweight, Without Type 2 Diabetes
The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase.
Participation in the main phase of the study will last about 75 weeks. Participants with prediabetes will continue in the extension phase for another 2 years.
Inclusion: Have Body Mass Index (BMI) at screening of the following:; 30 kilogram per square meter (kg/m2) OR; 27 kg/m2 with at least one of the following weight-related health conditions at screening:; high blood pressure; dyslipidemia; obstructive sleep apnea, or; heart disease; Have a stable body weight (<5% body weight change) for 90 days prior to screening; Have a history of at least one self-reported unsuccessful dietary effort to reduce body weight.
Exclusion: Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening); Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening); Have had within 90 days prior to screening:; heart attack; stroke; coronary artery revascularization; unstable angina, or; hospitalization due to congestive heart failure; Have taken medications or alternative remedies intended for weight loss within 90 days of screening; Have type 1 diabetes or type 2 diabetes; Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure.